Dr. Loren T. Niklason, Co-Developer of Breast Tomosynthesis Joins Hologic as Director of Tomosynthesis Programs

BEDFORD, Mass., Jan. 19, 2005 /PRNewswire-FirstCall/ -- Hologic, Inc. (NASDAQ: HOLX), a leading provider of women's diagnostic imaging systems and state-of- the-art digital imaging systems today announced that Dr. Loren T. Niklason has joined the company as Director of Tomosynthesis Programs. In this newly created position, Dr. Niklason reports directly to Jay A. Stein, Ph.D., Chief Technical Officer. As Director of Tomosynthesis Programs, Dr. Niklason will provide direction, support and assistance to Hologic's research and development efforts for tomosynthesis.

Dr. Niklason has an extensive background in digital imaging technology. He was one of the original developers of breast tomosynthesis while employed as a medical physicist in the department of radiology at the Massachusetts General Hospital in Boston. Dr. Niklason has enjoyed a success-based career and is internationally known and respected among his peers in medical imaging.

Tomosynthesis is a 3-D imaging technology that involves the acquisition of multiple images of a stationary compressed breast from different angles during a short scan. Hologic first demonstrated tomosynthesis with patient images and a prototype system as an add-on to its Selenia full field digital mammography system at the Radiological Society of North America meeting in Chicago in November 2003. Clinical trials began in the summer of 2004 at major university research sites in the United States.

"We are very pleased to have Dr. Niklason join Hologic to assist in the Company's research and development for tomosynthesis," said Jack Cumming, Hologic's Chairman and CEO. "As co-developer of breast tomosynthesis, Dr. Niklason brings a broad base of knowledge and expertise in the areas of clinical development and project management gained over a 20 year career in the medical industry. With multiple product phases planned for tomosynthesis development in 2005, Dr. Niklason's expertise integrated with our strong team of scientists and engineers make this a very exciting time for Hologic."

Dr. Niklason joins Hologic after serving as an advisor in the field of digital imaging. In addition, Dr. Niklason has held academic faculty positions at Harvard University Medical School and the University of Michigan.

Commenting on his appointment, Dr. Niklason stated, "I am honored to become a part of the Hologic team developing breast tomosynthesis, a technology that I believe will revolutionize breast cancer detection."

About Hologic

Hologic Inc. is a leading developer, manufacturer and supplier of medical imaging systems dedicated to serving the healthcare needs of women, and a leading developer of state-of-the-art digital imaging technology for general radiography and mammography applications. Hologic's core business units are focused on osteoporosis assessment, mammography and breast biopsy, direct-to- digital X-ray for general radiography applications and mini C-arm imaging for orthopedic applications. For more information visit

Forward Looking Disclaimer

Certain statements contained in this News Release constitute "forward- looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about Hologic's plans, objectives, expectations and intentions. Such statements include, without limitation, statements regarding Hologic's planned tomosynthesis development efforts, the expected contributions of Dr. Niklason to those efforts, and the expected benefits from the use of tomosynthesis imaging technology for the detection of breast cancer. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those anticipated. Hologic cannot assure that it will be able to complete the development of its tomosynthesis system on a timely basis, if at all, or that once developed, the system will perform as anticipated or be commercially successful. Factors that could cause actual results to materially differ include, without limitation, uncertainties inherent in the development of new products and technologies and the enhancement of existing products, including technical, manufacturing and regulatory risks, cost overruns and delays; the risk that newly introduced products may contain undetected errors or defects or otherwise not perform as anticipated; Hologic's ability to predict accurately the demand for its products, and products under development, and to develop strategies to address its markets successfully; the risk that technical innovations could render products marketed or under development by Hologic obsolete; competition with other products; Hologic's ability to attract and retain key technical personnel; and reimbursement policies for the use of the Company's products once developed. Other factors that could adversely affect Hologic's business and prospects are described in Hologic's filings with the Securities and Exchange Commission. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in Hologic's expectations or any change in events, conditions or circumstances on which any such statement is based.

   Glenn P. Muir                           Frances Crecco
   Executive Vice President & CFO          Director, Investor Relations
   Hologic, Inc.                           Hologic, Inc.
   (781) 999-7300                          (781) 999-7377

SOURCE: Hologic, Inc.

CONTACT: Glenn P. Muir Executive Vice President & CFO, +1-781-999-7300;
or Frances Crecco, Director, Investor Relations, +1-781-999-7377 both of
Hologic, Inc.

Web site: